Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
As part of an ongoing investigation of the safety of blood thinners, the US Food and Drug Administration (FDA) has released results from a large study comparing the relative risks of warfarin with those of dabigatran, a newer product. Analyses of adverse event reports submitted to the FDA have found unexpectedly high rates of bleeding and other adverse events as dabigatran prescribing has increased.
The study, which examined records for 134 000 Medicare patients aged 65 years or older, found that compared with warfarin, dabigatran use is associated with a lower risk of stroke, brain hemorrhage, and death (http://1.usa.gov/1mSL19n). However, dabigatran is associated with a higher rate of major gastrointestinal bleeding than warfarin. The study found that both drugs had about the same risk of myocardial infarction. Based on these results, the agency still considers dabigatran “to have a favorable benefit-to-risk profile.”
Kuehn BM. FDA Reviews Safety of Newer Anticoagulant. JAMA. 2014;311(24):2473. doi:10.1001/jama.2014.7364
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: